Pharvaris N.V.
Moderna's MRNA Phase 3 trial success drove a 177% stock surge, though shares cooled after a $2.6B convertible note offering. Analyst Marc Lichtenfeld sees potential upside. Pharvaris PHVS awaits Q3 data for deucrictibant, with M&A activity in the sector. AbbVie ABBV raised revenue guidance and continues dividend growth, with strong pipeline performance.
The article says a third-party “Claude Portfolio” account added positions in Pharvaris (PHVS) and Micron Technology (MU). For PHVS, it cites a prevention trial with results due before Sept. 30 and models about 80% success odds versus ~50% priced in, with a downside to around $16. For MU, it cites tight 2027 DRAM/HBM supply and a modeled ~14% upside.
Analysts issued multiple Wall Street calls, including UBS initiating Crescent Energy (CRGY) with Buy and $13 target, and UBS initiating SM Energy (SM) with Buy and $36 target. Raymond James reiterated Nvidia (NVDA) as strong buy. UBS reiterated SpaceX as buy, citing a July 16 Starship test flight. Deutsche Bank reiterated Tesla (TSLA) ahead of earnings. Citi lowered Microsoft (MSFT) target to $570 from $620.
Over the past 7 days, alphai's AI scored 1 news story mentioning PHVS (Pharvaris N.V.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PHVS coverage spans insider activity, financial news and market movers.
In the last 30 days, PHVS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($80K). The most active reporter was Modig Berndt, Chief Executive Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential catalyst in weeks; stock could rally on positive data or fall sharply on disappointment.
Near-term catalyst framing around the prevention trial could drive speculative positioning and volatility into the Sep 30 window.
Biotech initiation with a quantified PT can meaningfully affect risk appetite for the name.
Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).
This is an insider sale disclosure; it may slightly affect sentiment but does not change fundamentals by itself.
alphai scores every news story that mentions PHVS with an AI model for sentiment and relevance, and aggregates insider trades from Pharvaris N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Moderna's MRNA Phase 3 trial success drove a 177% stock surge, though shares cooled after a $2.6B convertible note offering. Analyst Marc Lichtenfeld sees potential upside. Pharvaris PHVS awaits Q3 data for deucrictibant, with M&A activity in the sector. AbbVie ABBV raised revenue guidance and continues dividend growth, with strong pipeline performance.
3 min readThe article says a third-party “Claude Portfolio” account added positions in Pharvaris (PHVS) and Micron Technology (MU). For PHVS, it cites a prevention trial with results due before Sept. 30 and models about 80% success odds versus ~50% priced in, with a downside to around $16. For MU, it cites tight 2027 DRAM/HBM supply and a modeled ~14% upside.
5 min readAnalysts issued multiple Wall Street calls, including UBS initiating Crescent Energy (CRGY) with Buy and $13 target, and UBS initiating SM Energy (SM) with Buy and $36 target. Raymond James reiterated Nvidia (NVDA) as strong buy. UBS reiterated SpaceX as buy, citing a July 16 Starship test flight. Deutsche Bank reiterated Tesla (TSLA) ahead of earnings. Citi lowered Microsoft (MSFT) target to $570 from $620.
7 min readPharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).
4 min readSchikan Johannes Gerardus Christiaan Petrus sold 37,600 shares of Pharvaris N.V. (PHVS) at an average of $35.41 ($35.05–$35.49, $1.33M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readLesage Anne (Chief Early Development) sold 37,700 indirectly-held shares of Pharvaris N.V. (PHVS) at an average of $35.41 ($35.05–$35.49, $1.33M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readLesage Anne (Chief Early Development) sold 38,472 shares of Pharvaris N.V. (PHVS) at an average of $35.37 ($35.05–$35.48, $1.36M total) across 3 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readLu Peng (Chief Medical Officer) sold 29,700 shares of Pharvaris N.V. (PHVS) at an average of $34.30 ($34.00–$35.09, $1.02M total) across 3 trades over 2026-06-25 to 2026-06-26 under a Rule 10b5-1 trading plan.
2 min readMonges Viviane sold 9,667 shares of Pharvaris N.V. (PHVS) at $30.29 ($0.29M total) on 2026-05-21.
2 min readNijdam Anna (Principal Accounting Officer) sold 1,829 shares of Pharvaris N.V. (PHVS) at $30.60 on 2026-05-21.
1 min read
